These findings challenge the traditional assumption that high CD16/CD56 expression is required for γδ T cell potency (74–76), highlighting that durable therapeutic efficacy may instead stem from enhanced TCR-driven responses and longevity within the tumor-bearing host. The gene discussed is NCAM1; the disease is neoplasm.